Best Stocks Under $1.00 for 2019

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Interpace Diagnostics Group (NASDAQ:IDXG)

Stock Price: $0.93
Market Cap: $27.73 million
P/E Ratio: -1.2
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $3.55 (279.9% Upside)

Interpace Diagnostics Group logoInterpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
#2 - Capstone Turbine (NASDAQ:CPST)

Stock Price: $0.81
Market Cap: $58.10 million
P/E Ratio: -4.1
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $2.1250 (161.7% Upside)

Capstone Turbine logoCapstone Turbine Corporation develops, manufactures, markets, and services microturbine technology solutions for use in stationary distributed power generation applications worldwide. It offers microturbine units, components, and various accessories for applications, including cogeneration comprising combined heat and power (CHP) and integrated CHP, as well as combined cooling, heat, and power; and renewable energy, natural resources, and critical power supply. The company's microturbines are also used as battery charging generators for hybrid electric vehicle applications. It also provides various accessories, including rotary gas compressors with digital controls; heat recovery modules for CHP applications; dual mode controllers that allow automatic transition between grid connect and stand-alone modes; batteries with digital controls for stand-alone or dual-mode operations; batteries with digital controls; power servers for multipacked installations; protocol converters for Internet access; packaging options; and miscellaneous parts, such as frames, exhaust ducting, backflow dampers, and installation hardware. In addition, the company remanufactures microturbine engines; and provides after-market parts and services. It markets and sells its products primarily through distributors and original equipment manufacturers. Capstone Turbine Corporation was founded in 1988 and is headquartered in Van Nuys, California.
#3 - AVEO Pharmaceuticals (NASDAQ:AVEO)

Stock Price: $0.62
Market Cap: $75.90 million
P/E Ratio: -3.9
Consensus Rating: Buy
Ratings Breakdown: 3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $2.20 (255.9% Upside)

AVEO Pharmaceuticals logoAVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
#4 - Synergy Pharmaceuticals (NASDAQ:SGYP)

Stock Price: $0.31
Market Cap: $69.45 million
P/E Ratio: -0.3
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $7.00 (2,158.1% Upside)

Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
#5 - Endologix (NASDAQ:ELGX)

Stock Price: $0.54
Market Cap: $60.03 million
P/E Ratio: -1.1
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $3.40 (529.6% Upside)

Endologix logoEndologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions which allows physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Ovation, Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
#6 - Achaogen (NASDAQ:AKAO)

Stock Price: $0.92
Market Cap: $65.49 million
P/E Ratio: -0.3
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $10.1429 (1,005.1% Upside)

Achaogen logoAchaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
#7 - Ideal Power (NASDAQ:IPWR)

Stock Price: $0.52
Market Cap: $4.62 million
P/E Ratio: -0.7
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $1.6667 (220.5% Upside)

Ideal Power logoIdeal Power Inc. develops power conversion solutions with a focus on solar and storage, microgrid, and stand-alone energy storage applications. It operates through two Divisions, Power Conversion Systems and B-TRAN. The Power Conversion Systems Division focuses on its Power Packet Switching Architecture technology. The B-TRAN Division develops its Bi-directional bi-polar junction TRANsistor solid state switch technology. The company's principal products include 30-kilowatt(kW) power conversion systems, such as two-port and multi-port products. It also offers 30kW SunDial, a PV string inverter, which is field upgradable through the addition of a drop-in second DC port to connect batteries to a solar PV array; and The SunDial Plus, such as the PV inverter and the second DC battery port. The company sells its products primarily to systems integrators in the United States. The company was formerly known as Ideal Power Converters Inc. and changed its name to Ideal Power Inc. in July 2013. Ideal Power Inc. was founded in 2007 and is headquartered in Austin, Texas.
#8 - Regulus Therapeutics (NASDAQ:RGLS)

Stock Price: $0.99
Market Cap: $8.66 million
P/E Ratio: -0.1
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $1.1250 (13.6% Upside)

Regulus Therapeutics logoRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
#9 - Weatherford International (NYSE:WFT)

Stock Price: $0.86
Market Cap: $879.11 million
P/E Ratio: -1.5
Consensus Rating: Hold
Ratings Breakdown: 4 Buy Ratings, 10 Hold Ratings, 4 Sell Ratings.
Consensus Price Target: $2.0738 (141.1% Upside)

Weatherford International logoWeatherford International plc operates as a multinational oilfield service company worldwide. It offers equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells. The company operates in two segments, Western Hemisphere and Eastern Hemisphere. It offers artificial-lift systems, including reciprocating rod, progressing cavity pumping, gas, hydraulic, plunger, and hybrid lift systems, as well as related automation and control systems; pressure pumping and reservoir stimulation services, such as acidizing, fracturing and fluid systems, cementing, and coiled-tubing intervention; and drill stem test tools, and surface well testing and multiphase flow measurement services. The company also provides safety, down hole reservoir monitoring, flow control, and multistage fracturing systems; sand-control technologies, and production and isolation packers for maximum production with minimal cost; liner hangers to suspend a casing string in high-temperature and high-pressure wells; cementing products, including plugs, float and stage equipment, and torque-and-drag reduction technology to operators for zonal isolation; and pre-job planning and installation services. In addition, it offers directional, and logging and measurement while drilling systems; rotary-steerable systems; high-temperature and high-pressure sensors, drilling reamers, and circulation subs; managed pressure drilling, conventional mud-logging, drilling instrumentation, gas analysis, well site consultancy, open hole and cased-hole logging services; reservoir solutions and software products; and remediation services. Further, the company provides equipment and drilling tools; tubular handling, management, and connection services; equipment rental services; and onshore contract drilling and related services, as well as operates a fleet of land drilling and work over rigs. The company was founded in 1972 and is headquartered in Baar, Switzerland.
#10 - Sanchez Energy (NYSE:SN)

Stock Price: $0.38
Market Cap: $33.26 million
P/E Ratio: -1.2
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $2.3429 (524.3% Upside)

Sanchez Energy logoSanchez Energy Corporation, an independent exploration and production company, focuses on the acquisition and development of U.S. onshore unconventional oil and natural gas resources. It engages in the horizontal development of resources from the Eagle Ford Shale in South Texas. It also holds an undeveloped acreage position in the Tuscaloosa Marine Shale (TMS) in Mississippi and Louisiana. As of December 31, 2017, the company had assembled approximately 285,000 net acres in the Eagle Ford Shale; and owned approximately 37,000 net acres in the TMS. Sanchez Energy Corporation was founded in 2011 and is headquartered in Houston, Texas.
#11 - Cloud Peak Energy (NYSE:CLD)

Stock Price: $0.60
Market Cap: $44.81 million
P/E Ratio: -1.4
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 4 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $3.40 (470.9% Upside)

Cloud Peak Energy logoCloud Peak Energy Inc. produces coal in the Powder River Basin and the United States. The company operates through Owned and Operated Mines, and Logistics and Related Activities. It owns and operates three surface coal mines comprising the Antelope Mine and the Cordero Rojo Mine located in Wyoming; and the Spring Creek Mine located in Montana. These mines produce subbituminous thermal coal with low sulfur content. The company sells its coal primarily to domestic and foreign electric utilities. As of December 31, 2017, it controlled approximately 1.0 billion tons of proven and probable reserves. The company also has two development projects comprising the Youngs Creek project, an undeveloped surface mine project located in Wyoming; and the Big Metal project located in southeast Montana. In addition, it offers logistics and related services, including the purchase of coal from third parties, as well as the contracting and coordination of the transportation and other handling services from third-party operators. Cloud Peak Energy Inc. was founded in 1993 and is headquartered in Gillette, Wyoming.
#12 - Enterprise GP (NYSE:EPE)

Stock Price: $0.73
Market Cap: $179.86 million
P/E Ratio: -1.9
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $2.3333 (218.4% Upside)

Enterprise GP logoEP Energy Corporation, an independent exploration and production company, engages in the exploration for and the acquisition, development, and production of oil, natural gas, and natural gas liquids in the United States. The company has interests in three primary areas, such as the Permian basin in West Texas; the Eagle Ford Shale in South Texas; and the Altamont Field in the Uinta basin in Northeastern Utah. As of December 31, 2017, it had proved reserves of 392.1 million barrels of oil equivalent and had average net daily production of 82,257 barrel of oil equivalent/per day. The company primarily sells its oil and natural gas production to third parties. EP Energy Corporation was founded in 2013 and is headquartered in Houston, Texas.
#13 - GASTAR EXPL INC/SH (NYSEAMERICAN:GST)

Stock Price: $0.06
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 2 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $0.8767 (1,462.7% Upside)

GASTAR EXPL INC/SH logoGastar Exploration Inc., an independent energy company, engages in the exploration, development and production of oil, condensate, natural gas, and natural gas liquids in the United States. Its principal activities include the identification, acquisition, exploration, and development of oil and natural gas properties on unconventional reserves, such as shale resource plays. The company holds interests in the oil and natural gas-rich reservoirs, including the Oswego limestone, Meramec, and Osage bench formations within the Mississippi Lime; and the Woodford shale formations. As of February 28, 2018, its principal assets included the STACK play covering approximately 67,800 net acres located in the Mid-Continent area of the United States. The company was formerly known as Gastar Exploration Ltd. and changed its name to Gastar Exploration Inc. in January 2014. Gastar Exploration Inc. is based in Houston, Texas.
#14 - Rite Aid (NYSE:RAD)

Stock Price: $0.80
Market Cap: $862.31 million
P/E Ratio: -39.9
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $2.20 (175.0% Upside)

Rite Aid logoRite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. It operates through two segments, Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment sells prescription drugs and a range of other merchandise, including over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other every day and convenience products. It also operates retail clinics that provide treatment for common conditions; and a range of preventive services comprising screenings, medical tests, immunizations, and basic physical exams. In addition, this segment offers healthcare coaching and disease management services. The Pharmacy Services segment provides pharmacy benefit management (PBM) services and a range of pharmacy-related services. This segment also performs prescription adjudication services for other PBMs; and offers integrated mail-order, specialty and compounding pharmacy, and infertility treatment services, as well as drug benefits under the federal government's Medicare Part D program. As of April 12, 2018, the company operated approximately 2,548 stores in 19 states. Rite Aid Corporation was founded in 1927 and is headquartered in Camp Hill, Pennsylvania.
#15 - New Gold (NYSEAMERICAN:NGD)

Stock Price: $0.85
Market Cap: $734.20 million
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 7 Hold Ratings, 3 Sell Ratings.
Consensus Price Target: $1.6167 (90.7% Upside)

New Gold logoNew Gold Inc., an intermediate gold mining company, engages in the development and operation of mineral properties. It primarily explores for gold, silver, and copper deposits. The company's operating properties include the New Afton project located near Kamloops, British Columbia, Canada; the Mesquite mine located in Imperial County, California, the United States; and the Cerro San Pedro mine located in the state of San Luis Potosí, Mexico. It also holds 100% interests in the Rainy River project located in Ontario, Canada; and the Blackwater project located in south-central British Columbia, Canada. The company was founded in 1980 and is headquartered in Toronto, Canada.
#16 - Pier 1 Imports (NYSE:PIR)

Stock Price: $0.90
Market Cap: $76.98 million
P/E Ratio: 4.3
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 5 Hold Ratings, 5 Sell Ratings.
Consensus Price Target: $1.5143 (68.3% Upside)

Pier 1 Imports logoPier 1 Imports, Inc. engages in the retail sale of decorative accessories, furniture, candles, housewares, gifts, and seasonal products. It offers decorative accents and textiles, such as rugs, wall decorations and mirrors, pillows, bedding, lamps, vases, dried and artificial flowers, baskets, ceramics, dinnerware, candles, fragrances, gifts, and seasonal items; and furniture and furniture cushions that are used in living, dining, office, kitchen and bedroom areas, sunrooms, and patios. As of march 3, 2018, the Company operated 928 stores in the United States and 75 stores in Canada It also operates e-Commerce Website, pier1.com. The company was founded in 1962 and is headquartered in Fort Worth, Texas.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel